Harriet Kluger, MD
Cards
About
Titles
Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology
Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Vice Chair for Collaborative Research, Internal Medicine; Chief, Division of Skin and Kidney Cancer; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical OncologyBiography
Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis.
Please visit the lab website at:
Appointments
Medical Oncology
ProfessorPrimaryDermatology
ProfessorSecondary
Other Departments & Organizations
- Dermatology
- Developmental Therapeutics
- Discovery to Cure Internship
- Internal Medicine
- K12 Calabresi Immuno-Oncology Training Program (IOTP)
- Medical Oncology
- Skin & Kidney Cancer Program
- SPORE in Skin Cancer
- Subset Medical Oncology Faculty
- WHRY Pilot Project Program Investigators
- Women's Health Research at Yale
- Yale Cancer Center
- Yale Center for Immuno-Oncology
- Yale Medicine
- Yale Ventures
- YCC Diversity, Equity, and Inclusion
Education & Training
- Fellow
- Yale University School of Medicine (2002)
- Resident
- University of New Mexico (1995)
- MD
- Tel Aviv University (1993)
Research
Clinical Care
Overview
Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis.
Clinical Specialties
Fact Sheets
Merkel Cell Carcinoma (MCC)
Learn More on Yale MedicineMelanoma
Learn More on Yale MedicineSkin Cancer
Learn More on Yale MedicineKidney Cancer
Learn More on Yale Medicine
Yale Medicine News
Links & Media
News
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.